Investor Alert

NeuBase Therapeutics Inc.



After Hours

 --Quotes are delayed by 20 min

Nov 26, 2021, 1:31 p.m.





0.00 0.00%


Volume 56

Quotes are delayed by 20 min


Previous close

$ 3.26

$ 3.10


-0.16 -4.91%

Day low

Day high




52 week low

52 week high




Dov A. Goldstein

Currently, Dov A. Goldstein holds the position of Chief Financial & Business Officer at Indapta Therapeutics, Inc. He is also on the board of ADMA Plasma Biologics, Inc., Geom Therapeutics, Inc., NeuBase Therapeutics, Inc. and Gain Therapeutics, Inc.

In his past career he held the position of Chief Executive Officer & Director at GO D.M. Investments Ltd., Chief Executive Officer & Director at RIGImmune, Inc., Chief Financial Officer for Schrödinger, Inc., Director-Venture Analysis at HealthCare Ventures LLC, Director at Durata Therapeutics, Inc., Chief Financial Officer & Executive Vice President of Vicuron Pharmaceuticals LLC, Chief Financial Officer for Loxo Oncology, Inc. and Operating Partner at Aisling Capital LLC.

He received an undergraduate degree from Stanford University, an MBA from Columbia Business School, a doctorate from Yale School of Medicine and an undergraduate degree from Tel-Aviv University.


Date Shares Transaction Value
06/18/2021 8,000   Acquisition at $4.75 per share. 38,000
04/26/2021 12,000   Acquisition at $5 per share. 60,000
04/30/2020 10,000   Acquisition at $6 per share. 60,000

Officers and Executives

Dr. Dietrich A. Stephan
Chairman, President, CEO & Chief Financial Officer
Dr. William R. Mann
Chief Operating Officer
Mr. Robert Friedlander
Chief Medical Officer
Dr. Curt W. Bradshaw
Chief Scientific Officer
Dr. Sandra Porcile Rojas-Caro
Chief Medical Officer
Dr. Anthony Rossomando
Chief Technology Officer
Ms. Shannon McCarthy
Chief People Officer
Dr. Dov A. Goldstein
Independent Director
Dr. Franklyn G. Prendergast
Independent Director
Mr. Eric I. Richman
Independent Director
Mr. Gerald J. McDougall
Independent Director
Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
Powered by StockTwits
Link to MarketWatch's Slice.